TECVAYLI®
(teclistamab-cqyv) Injection for subcutaneous use
10 mg/mL and 90 mg/mL

You are cordially invited to attend a non-CME educational program

A New 2L+ Combination Therapy for Adults With RRMM After a PI and an Immunomodulatory Agent



Presented by

Kim Burney, RN BSN, MSNed, OCN

Oncology Clinical Educator, an employee of Johnson & Johnson

Date

Thursday, November 12, 2026 at 6:00 PM Eastern Time

Location

Noble Fare
321 Jefferson Street,
Savannah, Georgia 31401
(912) 443-3210

We look forward to your participation in this informative discussion. Reserve your spot now by contacting your Johnson & Johnson Representative, Kim Burney at kburney@its.jnj.com (470) 366-6432

Please RSVP one (1) week prior to the program date

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Johnson & Johnson. Speakers are paid consultants presenting on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The personal information you provide may be used to contact you about your request to attend the Johnson & Johnson educational program using your preferred method of communication as indicated by you. This information may be shared with Johnson & Johnson, its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.

INDICATIONS AND USAGE

TECVAYLI® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma:

- in combination with daratumumab and hyaluronidase-fihj in patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
- as monotherapy, in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity.

Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious, life-threatening, or fatal reactions, can occur in patients receiving TECVAYLI. Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI until neurologic toxicity resolves or permanently discontinue based on severity.

TECVAYLI is available only through a restricted program called the TECVAYLI and TALVEY® Risk Evaluation and Mitigation Strategy (REMS).

Please see the following page for additional Important Safety Information and read full Prescribing Information, including Boxed WARNING, for TECVAYLI.

Johnson&Johnson © Johnson & Johnson and its affiliates 2026 04/26 cp-440811v3